Navigation Links
Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
Date:11/10/2011

sol generators and patient interface systems for clinical studies, and, if approved, for commercialization of drug and combination drug-device products, including risks of technology transfers to contract manufacturers and problems or delays encountered by Discovery Labs, its contract manufacturers or suppliers in manufacturing drug products, drug substances and other materials and capillary aerosol generators and patient interface systems on a timely basis or in an amount sufficient to support Discovery Labs' development efforts and, if approved, commercialization; the risk that Discovery Labs may be unable to identify potential strategic partners or collaborators to develop and commercialize its products, if approved, in a timely manner, if at all; the risk that Discovery Labs will not be able in a changing financial market to raise additional capital or enter into strategic alliances or collaboration agreements, or that the ongoing credit crisis will adversely affect the ability of Discovery Labs to fund its activities, or that additional financings could result in substantial equity dilution; the risk that Discovery Labs will not be able to access credit from its committed equity financing facility (CEFF), or that the minimum share price at which Discovery Labs may access the CEFF from time to time will prevent Discovery Labs from accessing the full dollar amount potentially available under the CEFF; the risk that Discovery Labs or its strategic partners or collaborators will not be able to retain, or attract, qualified personnel; the risk that Discovery Labs will be unable to maintain compliance with The Nasdaq Capital Market listing requirements, which could cause the price of Discovery Labs' common stock to decline; the risk that recurring losses, negative cash flows and the inability to raise additional capital could threaten Discovery Labs' ability to continue as a going concern; the risks that Discovery Labs may be unable to maintain and protect the patent
'/>"/>
SOURCE Discovery Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
2. Concentric Named Professional Agency of Record for Discovery Labs SURFAXIN(R)
3. ChanTest to Highlight the Worlds Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Ion Channel Targets, Booth 5
4. Biotechnology & Drug Discovery Markets Push Up Demand for Lab Automation Products, According to a New Report by Global Industry Analysts
5. Assay Designs(TM), Inc. and the Spinal Muscular Atrophy Foundation Announce Collaboration To Accelerate the Discovery of New Therapeutics for Spinal Muscular Atrophy (SMA)
6. ChanTest to Highlight the Worlds Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Assays & Cellular Targets Conference, Booth 11
7. Affitech Announces Second Milestone in Roche Antibody Discovery Collaboration
8. The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline
9. Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline
10. deCODE Discovery Sheds Light on Risk of the Most Common Form of Skin Cancer
11. Global Drug Discovery Technologies Market to Exceed $57 Billion by 2012, According to a New Report by Global Industry Analysts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)...  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" ... with G-treeBNT (ReGenTree LLC) has retained Ora, Inc. ... the orphan disorder, neurotrophic keratopathy (NK), and a ... (DES) in the U.S.  Both trials will be ... Each of these eye disorders was being targeted ...
(Date:4/16/2015)... PHOENIX, AZ (PRWEB) April 16, 2015 ... and makes it easier for research institutions to learn ... collect clinical data. , The timing is ideal since ... on Tuesday. Research Kit is an open-source framework for ... 9. It provides a way for researchers to collect ...
(Date:4/16/2015)... 2015 Avelas Biosciences, an in vivo ... announced today that it has initiated a Phase 1b ... women with primary, non-recurrent breast cancer undergoing surgery. In ... addition of Steven Chen , M.D., as vice ... dose escalation study will enroll up to 39 women ...
(Date:4/16/2015)... and MENLO PARK, Calif. , April ... DMPI) (DelMar and the Company), a biopharmaceutical company focused ... orphan drug indications, today announced that the Mayo ... clinical trial site for the ongoing, multicenter Phase I/II ... (GBM), the most common and deadly form of human ...
Breaking Biology Technology:RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Infographic Illustrates Potential for Research Kit to Impact Clinical Research 2Infographic Illustrates Potential for Research Kit to Impact Clinical Research 3Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5
... in Janesville last week as General Motors announced it will ... a decision that will keep high-wage manufacturing jobs in southern ... in the Janesville line means the plant will stay open ... whether the plants total of 3,900 jobs will grow or ...
... of North Prairie, Wisconsin, has signed a contract with ... new software is fully integrated with the rest of ... chain management and financial applications, which the company implemented ... cases used primarily by grocery, convenience, and drug store ...
... Information Systems employees will be participating for the ... management students at Blackhawk Technical College , located ... a comprehensive experience for students as they research a ... technology business solutions to local businesses. , ,As ...
Cached Biology Technology:GM Choice is Great News, But Wisconsins Economy Must Keep on Truckin to Prosper in a New Era 2Zero Zone Adds Sales and Marketing Automation Tools 2
(Date:3/19/2015)... , March 19, 2015  NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces its ... a news clip that aired this week on ... . In a segment "The Next Great Thing", ... ,a new way to pay, and ,a really big breakthrough ...
(Date:3/17/2015)... Minn. , March 17, 2015 ... technology company specializing in clinical study management systems, ... be in attendance at ARENA,s Outsourcing in Clinical ... NC.  This event provides an excellent forum for ... easy-to-use, flexible and affordable software-as-a-service (SaaS) eClinical technology ...
(Date:3/17/2015)... YORK , March 17, 2015  MecklerMedia ... the largest exhibition for service robots ever held ... RoboUniverse takes place on May 11-13, 2015 at ... and exhibitors for the event include: Acorn Product ... Control; EZ-Robot; Infranor; Kinova Robotics; Littler; NewBotic Corporation; ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
... "smart village" built in Malaysia provides a potential ... sustainable environment, say international experts meeting in California,s ... built north-east of Kuala Lumpur, consists of 100 ... and a creative, closed-loop agricultural system designed to ...
... Orleans, LA Research conducted by Jesus Lovera, MD, Assistant ... and colleagues has shown that stress management treatment significantly reduced ... sclerosis (MS) over the course of treatment. These lesions are ... The work is published ahead of print and is now ...
... determine much about you, but environment can have a strong ... can last a lifetime. In a study published online ... for the first time shown that the environment experienced in ... to DNA we are born with, that could have implications ...
Cached Biology News:Pioneering self-contained 'smart village' offers world model for rural poverty relief 2Pioneering self-contained 'smart village' offers world model for rural poverty relief 3Pioneering self-contained 'smart village' offers world model for rural poverty relief 4LSUHSC research finds treating stress prevented new MS brain lesions 2Differences between human twins at birth highlight importance of intrauterine environment 2
The Varian 4000 GC/MS system offers three easily switchable ionization configurations: internal ionization (II), external ionization (EI) or hybrid chemical ionization (CI)...
GeneRacer is an advanced RACE (rapid amplification of cDNA ends) technique that improves the efficiency of amplifying full-length 5' and 3' cDNA ends. With the GeneRacer Kit you can:...
... Mouse monoclonal [APS 26] to Presenilin ... an inherited form of the disease carry ... or the amyloid precursor protein (APP). These ... the longer form of amyloid-beta (main component ...
One-step, microplate or cuvet, colorimetric, linear detection range 6 mg/dL to 100mg/dL. Procedure: 15 min....
Biology Products: